Prognostic models for patients with PMF
| Prognostic model . | Risk groups and clinical relevance . |
|---|---|
| IPSS80 | |
| Risk factors (weight): | Low risk: 0 (median survival, 11.3 y) |
| • Age >65 y (1 point) | Intermediate-1 risk: 1 point (7.9 y) |
| • Constitutional symptoms (1 point) | Intermediate-2 risk: 2 points (4.0 y) |
| • Hemoglobin <10 g/dL (1 point) | High risk: ≥3 points (2.3 y) |
| • WBC count >25 × 109/L (1 point) | IPSS estimates survival at the time of diagnosis |
| • Circulating blasts ≥1% (1 point) | |
| DIPSS81 | |
| Risk factors (weight): | Low risk: 0 (median survival, >20 y) |
| • Age >65 y (1 point) | Intermediate-1 risk: 1-2 points (14.2 y) |
| • Constitutional symptoms (1 point) | Intermediate-2 risk: 3-4 points (4.0 y) |
| • Hemoglobin <10 g/dL (2 points) | High risk: 5-6 points (1.5 y) |
| • WBC count >25 × 109/L (1 point) | DIPSS can be applied anytime during clinical course |
| • Circulating blasts ≥ 1% (1 point) | |
| DIPSS-plus83 | |
| Risk factors (weight): | Low risk: 0 (median survival, 15 y) |
| • DIPSS score (DIPPS low = 0, DIPPS int-1 = 1 point, DIPPS int-2 = 2 points, DIPSS high = 3 points) | Intermediate-1 risk: 1 point (6.6 y) |
| • RBC transfusion need (1 point) | Intermediate-2 risk: 2-3 points (2.9 y) |
| • PLT count <100 × 109/L (1 point) | High risk: 4-6 points (1.3 y) |
| • Unfavorable karyotype* (1 point) | DIPSS-plus can be applied anytime during clinical course |
| Prognostic model . | Risk groups and clinical relevance . |
|---|---|
| IPSS80 | |
| Risk factors (weight): | Low risk: 0 (median survival, 11.3 y) |
| • Age >65 y (1 point) | Intermediate-1 risk: 1 point (7.9 y) |
| • Constitutional symptoms (1 point) | Intermediate-2 risk: 2 points (4.0 y) |
| • Hemoglobin <10 g/dL (1 point) | High risk: ≥3 points (2.3 y) |
| • WBC count >25 × 109/L (1 point) | IPSS estimates survival at the time of diagnosis |
| • Circulating blasts ≥1% (1 point) | |
| DIPSS81 | |
| Risk factors (weight): | Low risk: 0 (median survival, >20 y) |
| • Age >65 y (1 point) | Intermediate-1 risk: 1-2 points (14.2 y) |
| • Constitutional symptoms (1 point) | Intermediate-2 risk: 3-4 points (4.0 y) |
| • Hemoglobin <10 g/dL (2 points) | High risk: 5-6 points (1.5 y) |
| • WBC count >25 × 109/L (1 point) | DIPSS can be applied anytime during clinical course |
| • Circulating blasts ≥ 1% (1 point) | |
| DIPSS-plus83 | |
| Risk factors (weight): | Low risk: 0 (median survival, 15 y) |
| • DIPSS score (DIPPS low = 0, DIPPS int-1 = 1 point, DIPPS int-2 = 2 points, DIPSS high = 3 points) | Intermediate-1 risk: 1 point (6.6 y) |
| • RBC transfusion need (1 point) | Intermediate-2 risk: 2-3 points (2.9 y) |
| • PLT count <100 × 109/L (1 point) | High risk: 4-6 points (1.3 y) |
| • Unfavorable karyotype* (1 point) | DIPSS-plus can be applied anytime during clinical course |
RBC, red blood cell.
(+8,−7/7q,i(17)q,−5/5q,12p−,inv(3), 11q23 rearrangements).